viewRedx Pharma PLC

Redx Pharma plc - Redx to present two posters at AACR 2019

RNS Number : 3986U
Redx Pharma plc
29 March 2019


("Redx" or "the Company")


Redx Pharma to present two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting


Posters show that RXC004 has the ability to directly target tumour growth and stimulate the host immune response against tumours


Alderley Park, 29 March 2019Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the two abstracts submitted by the Company have been accepted for presentation as posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, taking place between 29 March and 3 April 2019.


Both posters relate to the Company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine (PORCN) inhibitor which targets the Wnt signalling pathway. The posters present preclinical data confirming the potential for RXC004 in modulating the immune system of the tumour microenvironment (poster #506) as well as preclinical data on the direct tumour-targeting effects of RXC004 in genetically-defined models of cancer (poster #3874).


Redx is evaluating RXC004 in an ongoing first-in-man clinical trial. The trial is a modular, multi-arm, multi-part, Phase 1/2a, adaptive design study whose primary objective is to evaluate the safety and tolerability of the drug in patients with advanced malignancies (ClinicalTrials.gov Identifier: NCT03447470). 


Richard Armer, Chief Scientific Officer of Redx Pharma plc commented, "We are delighted to be presenting again at this high-profile cancer conference. These poster presentations demonstrate our continued understanding of how RXC004 is able to have both direct and immunomodulatory effects on tumours in various preclinical cancer models. This preclinical data will inform design of future clinical studies to investigate the full potential of this mechanism."


Details of the poster presentations are as follows:



Abstract Title:

Wnt/β-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer

Session Title:

Metabolic Mechanisms That Modulate the Immune Response to Cancer


March 31, 2019, 1:00 PM - 5:00 PM CST


Poster Section 21

Poster Board Number:


Poster Number:




Abstract Title:

Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer

Session Title:

Novel Antitumor Agents 2


April 2, 2019, 1:00 PM - 5:00 PM CST


Poster Section 12

Poster Board Number:


Poster Number:




For further information, please contact:


Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer


Andrew Saunders, Chief Medical Officer




Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

T: +44 20 7894 7000

Phil Davies






WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson






FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin




About Redx Pharma Plc 

Redx is a UK-based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.


If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Redx Pharma PLC

Price: 57.5

Market: AIM
Market Cap: £112.27 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20